• Company
• Repotrectinib receives orphan drug designation in Korea
• by Eo, Yun-Ho May 17, 2024 05:47am

• Company
• Chinese Pharmas show presence at BIO Korea 2024
• by Moon, sung-ho May 16, 2024 05:48am

• Company
• Xcopri’s cumulative revenue surpasses KRW 1 trillion
• by Chon, Seung-Hyun May 16, 2024 05:48am

• Opinion
• [Reporter’s View] Drug Review Coordination Council
• by Kim, Jin-Gu May 16, 2024 05:48am

• Company
• "Camzyos, reimbursement would benefit gov and patients"
• by Eo, Yun-Ho May 16, 2024 05:48am

• Policy
• Multiple sclerosis drug Ocrevusis approved in Korea
• by Lee, Hye-Kyung May 14, 2024 05:48am

• Policy
• BIO KOREA 2024 concludes a success
• by Lee, Hye-Kyung May 14, 2024 05:48am

• Opinion
• [Reporter’s View] MFDS’ Regulatory Innovation 3.0
• by Lee, Hye-Kyung May 14, 2024 05:48am

• Company
• New oral psoriasis drug 'Sotyktu' available in hospitals
• by Eo, Yun-Ho May 14, 2024 05:48am

• Company
• Ryvrevant to lead market with Exkivity’s market withdrawal
• by Son, Hyung-Min May 14, 2024 05:48am